¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå : ½ÃÀå ±Ô¸ð - À¯Çüº°, ¿ëµµº°, À¯Åë ä³Îº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)
Global Aerosol Drug Delivery Devices Market Size Study, By Type (Inhaler, Nebulizer), By Application (COPD, Asthma, Cystic Fibrosis), By Distribution Channel, and Regional Forecasts 2022-2032
»óǰÄÚµå
:
1681304
¸®¼Ä¡»ç
:
Bizwit Research & Consulting LLP
¹ßÇàÀÏ
:
2025³â 03¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 285 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°è ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå ±Ô¸ð´Â 2023³â 263¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù.
ÀÌ ½ÃÀåÀº 2024³âºÎÅÍ 2032³â±îÁö 13.16%ÀÇ ³î¶ó¿î CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀÇ ¿øµ¿·ÂÀº È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡, ÷´Ü ÈíÀԱ⠱â¼ú äÅÃ, ÇコÄɾ ´ëÇÑ ÀÎ½Ä Áõ°¡ÀÔ´Ï´Ù. ÀçÅà ġ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¸é¼ ÈíÀÔ±â¿Í ºÐ¹«±â´Â õ½Ä, COPD, ³¶Æ÷¼º ¼¶À¯Áõ°ú °°Àº ¸¸¼º È£Èí±â ÁúȯÀ» °ü¸®ÇÏ´Â µ¥ ÇʼöÀûÀÎ µµ±¸·Î ÀÚ¸® ÀâÀ¸¸é¼ ÀÌ·¯ÇÑ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀº È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡ÀÔ´Ï´Ù. ¹Ì±¹ ÆóÇùȸ¿¡ µû¸£¸é, ¹Ì±¹¿¡¼´Â 1,170¸¸ ¸í ÀÌ»óÀÇ ¼ºÀÎÀÌ COPD Áø´ÜÀ» ¹Þ¾Ò½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)´Â 2030³â±îÁö Àü ¼¼°è »ç¸ÁÀÚ 5¸í Áß 1¸íÀÌ È£Èí±â ÁúȯÀ¸·Î »ç¸ÁÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ Åë°è´Â ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â°¡ Áúº´ °ü¸®¸¦ À§ÇÑ Áß¿äÇÑ ¼Ö·ç¼ÇÀÓÀ» °Á¶ÇÕ´Ï´Ù. ¶ÇÇÑ, ÇコÄɾ ´ëÇÑ Á¢±Ù¼º°ú ±â¼ú Çõ½Å¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Â °Íµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
ÈíÀÔ±â ÀåÄ¡, ƯÈ÷ »ç¿ë·® ÃßÀû ¹× ¼øÀÀµµ Çâ»óÀ» À§ÇÑ ¼¾¼¸¦ Æ÷ÇÔÇÑ ÀåÄ¡ÀÇ ±â¼ú ¹ßÀüÀº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ȯÀÚ°¡ Áúº´À» º¸´Ù È¿°úÀûÀ¸·Î °ü¸®ÇÏ°í º¸´Ù Á¤È®ÇÑ ¾à¹°Àü´ÞÀ» º¸ÀåÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ, Àü ¼¼°èÀûÀ¸·Î, ƯÈ÷ ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼ ÀÇ·á¿¡ ´ëÇÑ ÀνÄÀÌ Áö¼ÓÀûÀ¸·Î Çâ»óµÊ¿¡ µû¶ó ȯÀÚµéÀº º¸´Ù È¿°úÀûÀ¸·Î Áúº´À» °ü¸®Çϱâ À§ÇØ ÈíÀÔ±â¿Í ºÐ¹«±â¸¦ ¼±ÅÃÇÏ°Ô µÇ¾ú½À´Ï´Ù.
Äڷγª19 ÆÒµ¥¹ÍÀº Äڷγª19¿Í °°Àº È£Èí±â Áúȯ°ú ±× ÇÕº´ÁõÀ¸·Î ÀÎÇØ È£Èí±â Áö¿øÀÇ Çʿ伺ÀÌ ³ô¾ÆÁ³±â ¶§¹®¿¡ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå¿¡ ÀÌÁßÀ¸·Î ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ±×·¯³ª ÆÒµ¥¹ÍÀº ¶ÇÇÑ ¼¼°è °ø±Þ¸Á¿¡ È¥¶õÀ» ÀÏÀ¸ÄÑ ÀÌ·¯ÇÑ ÀåÄ¡ÀÇ »ý»ê¿¡ ÀϽÃÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ÆÒµ¥¹ÍÀ¸·Î ÀÎÇÑ ¾î·Á¿ò¿¡µµ ºÒ±¸Çϰí, ÀçÅÃÄ¡·á ¼ºñ½º Áõ°¡¿Í ½º¸¶Æ® ÈíÀÔ ÀåÄ¡ÀÇ Ã¤ÅÃÀ¸·Î ½ÃÀåÀº ¼ºÀå¼¼¸¦ À̾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå¿¡¼ ºÏ¹Ì´Â 2024³â Àüü ¸ÅÃâÀÇ 39% ÀÌ»óÀ» Â÷ÁöÇÏ¸ç °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À̴ ȣÈí±â ÁúȯÀÇ À¯º´·ü Áõ°¡, Àα¸ °í·ÉÈ, Àß ±¸ÃàµÈ ÀÇ·á ÀÎÇÁ¶ó¿¡ ±âÀÎÇÕ´Ï´Ù. ±×·¯³ª ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·á Á¢±Ù¼º °³¼±, ¿À¿°µµ Áõ°¡, Áß±¹ ¹× Àεµ¿Í °°Àº ±¹°¡¿¡¼ È£Èí±â Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â(Aerosol Drug Delivery Device) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, À¯Çüº°/¿ëµµº°/À¯Åë ä³Îº°/Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÃâ ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå ÁÖ¿ä ¿ä¾à
Á¦2Àå ¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå Á¤ÀÇ¿Í Á¶»ç ÀüÁ¦
Á¦3Àå ¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
- ½ÃÀå ±âȸ
Á¦4Àå ¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â »ê¾÷ ºÐ¼®
- Porter's Five Forces ¸ðµ¨
- PESTEL ºÐ¼®
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ÁÖ¿ä ¼º°ø Àü·«
- ÆÄ±«ÀûÀÎ µ¿Çâ
- ¾÷°è Àü¹®°¡ÀÇ °ßÇØ
- ¾Ö³Î¸®½ºÆ® Ãßõ »çÇ×°ú °á·Ð
Á¦5Àå ¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : À¯Çüº°(2022³â-2032³â)
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå : À¯Çüº° ¸ÅÃâ µ¿Ç⠺м®, 2022³â ¹× 2032³â
Á¦6Àå ¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¿ëµµº°(2022³â-2032³â)
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå : ¿ëµµº° ¸ÅÃâ µ¿Ç⠺м®, 2022³â ¹× 2032³â
- õ½Ä
- ¸¸¼º Æó¼â¼º ÆóÁúȯ(COPD)
- ³¶Æ÷¼º ¼¶À¯Áõ
Á¦7Àå ¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : À¯Åë ä³Îº°(2022³â-2032³â)
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå : À¯Åë ä³Îº° ¸ÅÃâ µ¿Ç⠺м®, 2022³â ¹× 2032³â
- ¼Ò¸Å ¾à±¹
- ÀÇ·á±â°ü ¾à±¹
- ¿Â¶óÀÎ ¾à±¹
Á¦8Àå ¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°(2022³â-2032³â)
- ºÏ¹ÌÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå
- À¯·´ÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå
- ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå
- ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå
Á¦9Àå °æÀï Á¤º¸
- ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
- AptarGroup, Inc.
- Koninklijke Philips NV
- AstraZeneca
- ÁÖ¿ä ½ÃÀå Àü·«
- ±â¾÷ °³¿ä
- AptarGroup, Inc.
- Koninklijke Philips NV
- AstraZeneca
Á¦10Àå Á¶»ç °úÁ¤
LSH
¿µ¹® ¸ñÂ÷
The global aerosol drug delivery devices market was valued at USD 26.33 billion in 2023, with expectations to grow at a remarkable compound annual growth rate (CAGR) of 13.16% from 2024 to 2032. This growth is driven by the rising prevalence of respiratory diseases, the adoption of advanced inhaler technologies, and increasing healthcare awareness. The growing demand for home-based treatments further contributes to this growth, with inhalers and nebulizers becoming essential tools for managing chronic respiratory conditions such as asthma, COPD, and cystic fibrosis.
A key factor behind the market's growth is the increasing prevalence of respiratory diseases. According to the American Lung Association, over 11.7 million adults in the U.S. have been diagnosed with COPD. The World Health Organization (WHO) projects that by 2030, respiratory diseases will account for nearly one in five deaths worldwide. These statistics underscore the importance of aerosol drug delivery devices as critical solutions for disease management. Furthermore, the growing emphasis on healthcare access and innovation is contributing to the market's expansion.
Technological advancements in inhaler devices, particularly those that include sensors for usage tracking and improved adherence, are accelerating market growth. These innovations help patients manage their diseases more effectively, ensuring more precise delivery of medications. Additionally, as healthcare awareness continues to improve globally, especially in regions like Asia-Pacific, patients are increasingly opting for inhalers and nebulizers to manage their conditions more effectively.
The COVID-19 pandemic had a dual impact on the aerosol drug delivery devices market. It caused a surge in demand for these devices, as respiratory diseases like COVID-19 and its complications led to an increased need for respiratory support. However, the pandemic also led to disruptions in the global supply chain, affecting the production of these devices temporarily. Despite the challenges posed by the pandemic, the market is expected to continue its growth trajectory, driven by the rise in home healthcare services and the adoption of smart inhalation devices.
North America holds the largest share of the aerosol drug delivery devices market, accounting for more than 39% of the total revenue in 2024. This is due to the increasing incidence of respiratory diseases, an aging population, and a well-established healthcare infrastructure. However, the Asia-Pacific region is expected to witness the fastest growth during the forecast period, driven by improved healthcare access, rising pollution levels, and a growing awareness of respiratory diseases in countries like China and India.
Major market players included in this report are:
- AptarGroup, Inc.
- Koninklijke Philips N.V.
- AstraZeneca
- Novartis AG
- OMRON Corporation
- Medline Industries, LP
- DRIVE MEDICAL GMBH & CO. KG
- Teva Pharmaceutical Industries Ltd
- Aerogen (Stamford Devices Limited Group)
- Sensirion AG
The detailed segments and sub-segments of the market are explained below:
By Type:
- Nebulizers
- Jet
- Mesh
- Active
- Passive
- Ultrasonic
- Inhaler
- Pressurized Metered-Dose Inhaler (pMDI)
- Dry-Powder Inhaler (DPI)
By Application:
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Other (Pulmonary Arterial Hypertension (PAH), etc.)
By Distribution Channel:
- Retail Pharmacies
- Institutional Pharmacies
- Online Pharmacies
By Region:
North America:
Europe:
- UK
- Germany
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
Asia Pacific:
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America:
Middle East & Africa:
- Saudi Arabia
- South Africa
- UAE
- Kuwait
Years considered for the study are as follows:
- Historical year - 2022
- Base year - 2023
- Forecast period - 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with country-level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand-side and supply-side analysis of the market.
Table of Contents
Chapter 1. Global Aerosol Drug Delivery Devices Market Executive Summary
- 1.1. Global Aerosol Drug Delivery Devices Market Size & Forecast (2022 - 2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Type
- 1.3.2. By Application
- 1.3.3. By Distribution Channel
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Aerosol Drug Delivery Devices Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Regulatory Frameworks
- 2.3.4.2. Technological Advancements
- 2.3.4.3. Environmental Considerations
- 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
Chapter 3. Global Aerosol Drug Delivery Devices Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Increasing Prevalence of Respiratory Diseases
- 3.1.2. Technological Advancements in Inhaler Devices
- 3.1.3. Growing Healthcare Awareness
- 3.2. Market Challenges
- 3.2.1. Regulatory Hurdles
- 3.2.2. Short-term Supply Chain Disruptions
- 3.3. Market Opportunities
- 3.3.1. Increased Adoption of Smart Inhalers
- 3.3.2. Expansion in Emerging Markets
- 3.3.3. Surge in Home Healthcare Adoption
Chapter 4. Global Aerosol Drug Delivery Devices Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top Investment Opportunities
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Aerosol Drug Delivery Devices Market Size & Forecasts by Type (2022 - 2032)
- 5.1. Segment Dashboard
- 5.2. Global Aerosol Drug Delivery Devices Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Nebulizers
- 5.2.2. Inhalers
Chapter 6. Global Aerosol Drug Delivery Devices Market Size & Forecasts by Application (2022 - 2032)
- 6.1. Segment Dashboard
- 6.2. Global Aerosol Drug Delivery Devices Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Asthma
- 6.2.2. Chronic Obstructive Pulmonary Disease (COPD)
- 6.2.3. Cystic Fibrosis
Chapter 7. Global Aerosol Drug Delivery Devices Market Size & Forecasts by Distribution Channel (2022 - 2032)
- 7.1. Segment Dashboard
- 7.2. Global Aerosol Drug Delivery Devices Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Retail Pharmacies
- 7.2.2. Institutional Pharmacies
- 7.2.3. Online Pharmacies
Chapter 8. Global Aerosol Drug Delivery Devices Market Size & Forecasts by Region (2022 - 2032)
- 8.1. North America Aerosol Drug Delivery Devices Market
- 8.1.1. U.S. Aerosol Drug Delivery Devices Market
- 8.1.1.1. Type Breakdown Size & Forecasts, 2022 - 2032
- 8.1.1.2. Application Breakdown Size & Forecasts, 2022 - 2032
- 8.1.2. Canada Aerosol Drug Delivery Devices Market
- 8.2. Europe Aerosol Drug Delivery Devices Market
- 8.2.1. U.K. Aerosol Drug Delivery Devices Market
- 8.2.2. Germany Aerosol Drug Delivery Devices Market
- 8.2.3. France Aerosol Drug Delivery Devices Market
- 8.2.4. Italy Aerosol Drug Delivery Devices Market
- 8.2.5. Spain Aerosol Drug Delivery Devices Market
- 8.3. Asia Pacific Aerosol Drug Delivery Devices Market
- 8.3.1. China Aerosol Drug Delivery Devices Market
- 8.3.2. India Aerosol Drug Delivery Devices Market
- 8.3.3. Japan Aerosol Drug Delivery Devices Market
- 8.3.4. Australia Aerosol Drug Delivery Devices Market
- 8.4. Latin America Aerosol Drug Delivery Devices Market
- 8.4.1. Brazil Aerosol Drug Delivery Devices Market
- 8.4.2. Argentina Aerosol Drug Delivery Devices Market
- 8.5. Middle East & Africa Aerosol Drug Delivery Devices Market
- 8.5.1. Saudi Arabia Aerosol Drug Delivery Devices Market
- 8.5.2. South Africa Aerosol Drug Delivery Devices Market
- 8.5.3. UAE Aerosol Drug Delivery Devices Market
Chapter 9. Competitive Intelligence
- 9.1. Key Company SWOT Analysis
- 9.1.1. AptarGroup, Inc.
- 9.1.2. Koninklijke Philips N.V.
- 9.1.3. AstraZeneca
- 9.2. Top Market Strategies
- 9.3. Company Profiles
- 9.3.1. AptarGroup, Inc.
- 9.3.2. Koninklijke Philips N.V.
- 9.3.3. AstraZeneca
Chapter 10. Research Process
- 10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
- 10.2. Research Attributes
°ü·ÃÀÚ·á